Published in Lab Chip on April 27, 2010
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Micro total analysis systems for cell biology and biochemical assays. Anal Chem (2011) 1.58
Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape. Proc Natl Acad Sci U S A (2011) 0.95
A multichannel dampened flow system for studies on shear stress-mediated mechanotransduction. Lab Chip (2012) 0.84
Variation in diffusion of gases through PDMS due to plasma surface treatment and storage conditions. Biomed Microdevices (2014) 0.80
Microfluidics and cancer: are we there yet? Biomed Microdevices (2013) 0.80
Analysis of a high-throughput cone-and-plate apparatus for the application of defined spatiotemporal flow to cultured cells. Biotechnol Bioeng (2013) 0.78
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol (1979) 6.96
Genetic determinants of cancer metastasis. Nat Rev Genet (2007) 6.38
Biological implications of polydimethylsiloxane-based microfluidic cell culture. Lab Chip (2009) 2.59
Continuous perfusion microfluidic cell culture array for high-throughput cell-based assays. Biotechnol Bioeng (2005) 2.45
A novel 3D mammalian cell perfusion-culture system in microfluidic channels. Lab Chip (2007) 2.03
Characterization of polydimethylsiloxane (PDMS) properties for biomedical micro/nanosystems. Biomed Microdevices (2005) 1.95
Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. Biomaterials (2009) 1.54
Design and integration of an all-in-one biomicrofluidic chip. Biomicrofluidics (2008) 1.33
A multipurpose microfluidic device designed to mimic microenvironment gradients and develop targeted cancer therapeutics. Lab Chip (2008) 1.30
Effect of channel geometry on cell adhesion in microfluidic devices. Lab Chip (2008) 1.03
Detachment of captured cancer cells under flow acceleration in a bio-functionalized microchannel. Lab Chip (2009) 1.01
Multi-step microfluidic device for studying cancer metastasis. Lab Chip (2007) 1.00
A self-contained microfluidic cell culture system. Biomed Microdevices (2009) 0.89
Continuous particle separation through deterministic lateral displacement. Science (2004) 5.60
Force mapping in epithelial cell migration. Proc Natl Acad Sci U S A (2005) 5.08
From the Cover: The dynamics of genomic-length DNA molecules in 100-nm channels. Proc Natl Acad Sci U S A (2004) 3.65
Statics and dynamics of single DNA molecules confined in nanochannels. Phys Rev Lett (2005) 3.63
Deterministic hydrodynamics: taking blood apart. Proc Natl Acad Sci U S A (2006) 3.38
Single molecule measurements of repressor protein 1D diffusion on DNA. Phys Rev Lett (2006) 2.81
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Restriction mapping in nanofluidic devices. Proc Natl Acad Sci U S A (2005) 2.28
Acceleration of emergence of bacterial antibiotic resistance in connected microenvironments. Science (2011) 2.26
Bacterial metapopulations in nanofabricated landscapes. Proc Natl Acad Sci U S A (2006) 2.26
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology (2005) 2.10
Critical particle size for fractionation by deterministic lateral displacement. Lab Chip (2006) 2.07
Electrodeless dielectrophoresis of single- and double-stranded DNA. Biophys J (2002) 1.97
Motion to form a quorum. Science (2003) 1.95
The homologous ABI5 and EEL transcription factors function antagonistically to fine-tune gene expression during late embryogenesis. Plant Cell (2002) 1.81
A DNA prism for high-speed continuous fractionation of large DNA molecules. Nat Biotechnol (2002) 1.78
Early identification of individuals with prostate cancer in negative biopsies. J Urol (2004) 1.78
In vivo and scanning electron microscopy imaging of up-converting nanophosphors in Caenorhabditis elegans. Nano Lett (2006) 1.73
The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. J Biol Chem (2011) 1.68
DNA confinement in nanochannels: physics and biological applications. Rep Prog Phys (2012) 1.65
Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clin Cancer Res (2002) 1.65
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med (2013) 1.63
Analysis of an activated ABI5 allele using a new selection method for transgenic Arabidopsis seeds. FEBS Lett (2004) 1.61
Single-molecule studies of repressor-DNA interactions show long-range interactions. Proc Natl Acad Sci U S A (2005) 1.60
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila) (2012) 1.57
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A (2002) 1.53
Retracted Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res (2008) 1.51
Enhanced Caenorhabditis elegans locomotion in a structured microfluidic environment. PLoS One (2008) 1.49
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology (2005) 1.48
Parallel microchannel-based measurements of individual erythrocyte areas and volumes. Biophys J (2003) 1.46
Biomarkers for prostate cancer. Annu Rev Med (2009) 1.45
Micro- and nanofluidics for DNA analysis. Anal Bioanal Chem (2004) 1.43
Computation of mutual fitness by competing bacteria. Proc Natl Acad Sci U S A (2008) 1.39
A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33
Deterministic separation of cancer cells from blood at 10 mL/min. AIP Adv (2012) 1.30
Excited-state lifetimes of far-infrared collective modes in proteins. Phys Rev Lett (2001) 1.30
Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". JAMA (2006) 1.26
Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 1.21
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol (2005) 1.13
Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. J Cell Biochem (2009) 1.12
Laser-induced ultrafast demagnetization in the presence of a nanoscale magnetic domain network. Nat Commun (2012) 1.11
Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res (2002) 1.08
Retracted Highly specific urine-based marker of bladder cancer. Urology (2005) 1.07
Retracted Functional characterization of the bladder cancer marker, BLCA-4. Clin Cancer Res (2004) 1.06
Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res (2005) 1.06
Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res (2006) 1.06
A majority of the cancer/testis antigens are intrinsically disordered proteins. J Cell Biochem (2011) 1.05
The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res (2003) 1.04
Crossing microfluidic streamlines to lyse, label and wash cells. Lab Chip (2008) 1.04
Retracted Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res (2007) 1.03
Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate (2010) 1.03
Sub-10 nm self-enclosed self-limited nanofluidic channel arrays. Nano Lett (2008) 1.03
Deterministic microfluidic ratchet. Phys Rev Lett (2009) 1.02
Cancer/testis antigens and urological malignancies. Nat Rev Urol (2012) 1.01
Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology (2004) 1.00
The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer. Prostate (2008) 0.99
Identification of calreticulin as a nuclear matrix protein associated with human colon cancer. J Cell Biochem (2003) 0.99
Cell motility and drug gradients in the emergence of resistance to chemotherapy. Proc Natl Acad Sci U S A (2013) 0.99
Minimization of thermodynamic costs in cancer cell invasion. Proc Natl Acad Sci U S A (2013) 0.98
Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol (2005) 0.98
Nuclear structure as a source of cancer specific biomarkers. J Cell Biochem (2008) 0.97
Collective escape of chemotactic swimmers through microscopic ratchets. Phys Rev Lett (2010) 0.97
Hydrodynamic metamaterials: microfabricated arrays to steer, refract, and focus streams of biomaterials. Proc Natl Acad Sci U S A (2008) 0.96
Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl (2012) 0.96
Role of majority and minority carrier barriers silicon/organic hybrid heterojunction solar cells. Adv Mater (2011) 0.95
Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther (2005) 0.95
Single sub-20 nm wide, centimeter-long nanofluidic channel fabricated by novel nanoimprint mold fabrication and direct imprinting. Nano Lett (2007) 0.95
Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape. Proc Natl Acad Sci U S A (2011) 0.95
Retracted Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology. Cancer Res (2005) 0.95
A nanofluidic railroad switch for DNA. Nano Lett (2006) 0.94
Microfluidic device for label-free measurement of platelet activation. Lab Chip (2008) 0.94